Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

ACCRUED EXPENSES AND LONG-TERM LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2022

Other accrued expenses consisted of the following as of March 31, 2022 and December 31, 2021:

SCHEDULE OF OTHER ACCRUED EXPENSES

	March 31, 2022		December 31, 2021
	(unaudited)
Accrued royalties	$	4,116	$	3,890
Contingent consideration		488		488
Operating lease liability		999		1,041
Financing lease liability		70		79
Deferred revenue		31		40
Interest payable		62		120
Warrant liability		8		71
Accrued sales and marketing - diagnostics		63		47
Accrued lab costs - diagnostics		185		228
Accrued professional fees		707		932
Taxes payable		269		245
Unclaimed property		565		565
All others		1,129		1,452
Total other accrued expenses	$	8,692	$	9,198

Long-term liabilities consisted of the following as of March 31, 2022 and December 31, 2021:

SCHEDULE OF LONG TERM LIABILITIES

	March 31, 2022		December 31, 2021
	(unaudited)
Uncertain tax positions	$	4,631	$	4,577
Deferred revenue		13		13
Other		41		58
Total other long-term liabilities	$	4,685	$	4,648